Wave Life Sciences LTD

Wave Life Sciences announced Q2 2026 financial results, highlighting progress in its obesity, AATD, and PNPLA3 liver disease programs, with a strong cash position extending runway into Q3 2028.

Wave Life Sciences Ltd. shareholders have voted to approve a scheme of arrangement to redomicile the company from Singapore.

Wave Life Sciences announced positive data from its RestorAATion-2 trial for WVE-006, showing potential to treat both lung and liver manifestations of AATD with a convenient, safe, and durable therapy.

Wave Life Sciences reported Q1 2026 financial results, highlighting advancements in its WVE-007 obesity program, WVE-006 AATD treatment, and WVE-008 liver disease program, while maintaining a strong cash position.

Wave Life Sciences has scheduled a Singapore High Court hearing for April 29, 2026, to advance its proposed redomiciliation to the United States.

Wave Life Sciences Ltd. announced a plan to redomicile its parent company from Singapore to the United States, aiming for administrative efficiencies and streamlined operations.

Wave Life Sciences reports on its Q2 2026 financial results, highlighting advancements in its RNA medicines pipeline, including positive interim data for WVE-007 and WVE-006, alongside a significant increase in R&D expenses and a decrease in cash reserves.

Wave Life Sciences reported a significant increase in revenue for Q1 2026, driven by collaboration agreements, while net loss decreased compared to the prior year.

Wave Life Sciences announced significant positive clinical data across its pipeline, including first-in-human RNA editing proof-of-mechanism and favorable regulatory feedback, alongside a reduced net loss for Q3 2025.

Wave Life Sciences reported a significant increase in net loss for the first half of 2025, driven by higher research and development expenses, while simultaneously announcing positive clinical data and advancement across its obesity, AATD, DMD, and Huntington's disease programs.

Wave Life Sciences reports its financial results for the first quarter of 2025, detailing progress in its RNA medicines platform and clinical programs.

Wave Life Sciences announced positive clinical data from its Huntington's disease and AATD programs, along with a financial update for the third quarter of 2024.

Wave Life Sciences Ltd. filed an amendment to its 2025 Annual Report to include required Part III disclosures and updated certifications.

Wave Life Sciences reported increased net losses in 2025 despite positive clinical trial data for its lead RNA medicine programs and a significant capital raise.

Wave Life Sciences Ltd. files an amendment to its 2024 annual report, primarily to include previously omitted information regarding executive compensation, corporate governance, and updated certifications.

Wave Life Sciences' 10-K filing summarizes the company's focus on RNA medicines, clinical program advancements, and financial results for the year ended December 31, 2024.

Wave Life Sciences has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and updated certifications.

Wave Life Sciences' 10-K filing provides a detailed overview of its share capital, governance, and shareholder rights, highlighting its focus on RNA medicines.

RA Capital Management, a significant shareholder and board member, increased its beneficial ownership in Wave Life Sciences Ltd. through multiple open market purchases.

A Wave Life Sciences Ltd. executive exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged trading plan.

Wave Life Sciences CFO Kyle Moran reported significant equity awards, including restricted stock units and stock options, alongside a tax-related share sale.

Wave Life Sciences CEO Paul Bolno reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of shares.

A Wave Life Sciences executive reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of ordinary shares.

Wave Life Sciences CTO Chandra Vargeese reported acquisition of restricted share units and stock options, alongside a tax-related sale of ordinary shares.

Wave Life Sciences Ltd. is seeking shareholder approval to restructure its corporate group by redomiciling its parent company to Delaware, USA.

Wave Life Sciences Ltd. has released its definitive proxy statement for the 2025 Annual General Meeting, detailing proposals for director elections, auditor re-appointment, executive and non-employee director compensation, and a significant increase in shares available for its equity incentive plan, while reporting continued net losses despite pipeline progress and recent capital raises.

Wave Life Sciences has scheduled its 2024 Annual General Meeting (AGM) for August 6, 2024, outlining proposals including the election of directors, auditor re-appointment, executive compensation approval, and an amendment to the equity incentive plan.

RA Capital Management reports a 17.1% stake in Wave Life Sciences as the company initiates a redomiciliation to Delaware via a Scheme of Arrangement.

RA Capital Management and its affiliates have significantly increased their beneficial ownership in Wave Life Sciences Ltd., now holding 17.5% of the common stock after recent open market purchases totaling over $54 million.

RA Capital Management's beneficial ownership in Wave Life Sciences has been diluted to 13.4% following a recent public equity offering by the issuer.

RA Capital Management, L.P. and its affiliates filed an amendment to their Schedule 13D, reporting a dilution of their beneficial ownership in Wave Life Sciences Ltd. to 14.6%.

Adage Capital Management, L.P. and its principals have reported beneficial ownership of 1,000,000 ordinary shares in Wave Life Sciences Ltd., representing 0.53% of the outstanding class.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 5,192,761.43 shares of Wave Life Sciences common stock, representing 2.8% of the class.

Adage Capital Management and its principals report a 5.35% beneficial ownership stake in Wave Life Sciences Ltd. as of December 31, 2025.

FMR LLC and its affiliates, including Abigail P. Johnson, reported beneficial ownership of 8.5% of Wave Life Sciences Ltd.'s common stock as of December 31, 2025.

Adage Capital Management, L.P. and its principals report a 9.65% beneficial ownership stake in Wave Life Sciences Ltd. as of June 30, 2025.

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 8.15% in Wave Life Sciences Ltd., totaling 12,516,500 ordinary shares.